SLC39A1 contributes to gemcitabine resistance of pancreatic ductal adenocarcinoma by activating AMPK signaling. (2024). Bangladesh Journal of Pharmacology, 19(2), 52-58. https://doi.org/10.3329/bjp.v19i2.72787